NeoGenomics Inc. Reports 2025 Earnings and Revenue Metrics
NeoGenomics Inc. (NASDAQ: NEO) released financial results for the first and second quarters of fiscal year 2025. The company’s earnings transcripts were published on April 28, 2026, through multiple financial news outlets.
Q1 2025 Financial Highlights
- Non‑GAAP Earnings per Share: $0.01
- Revenue: $187 million
The Q1 transcript, released by Nasdaq, details the company’s performance metrics and operational commentary.
Q2 2025 Financial Highlights
While the exact earnings figures for the second quarter are not provided in the input, the earnings transcript for Q2 2025 was also published on April 28, 2026, according to the Feed of The Motley Fool.
Company Overview
NeoGenomics operates a network of clinical laboratories offering a range of diagnostic services, including cytogenetics, fluorescence in‑situ hybridization (FISH), flow cytometry, morphology, anatomic pathology, and molecular genetic testing. Services target pathologists, oncologists, urologists, and hospitals. The company was listed on the Nasdaq following its IPO on November 2, 1999.
Key financial indicators as of the latest data:
- Market Capitalization: $1,078,892,416 USD
- 52‑Week High (Jan 11, 2026): $13.74
- 52‑Week Low (Jul 31, 2025): $4.72
- Close Price (Apr 26, 2026): $8.61
- Price‑to‑Earnings Ratio: –9.732 (negative, indicating a loss)
NeoGenomics’ revenue in Q1 2025 of $187 million represents a key component of its overall annual earnings profile, while the modest Non‑GAAP EPS of $0.01 reflects the company’s current profitability status. Further details from the Q2 transcript will provide additional insight into the company’s ongoing financial trajectory.
